{
    "root": "314914d1-c029-cfe6-e063-6394a90a54f4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ERIBULIN MESYLATE",
    "value": "20250327",
    "ingredients": [
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "ERIBULIN MESYLATE",
            "code": "AV9U0660CW"
        }
    ],
    "indications": "Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. ( 1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. ( 1.2 )",
    "contraindications": "Administer 1.4 mg/m 2 intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. ( 2.1 ) Reduce dose in patients with hepatic impairment or with moderate or severe renal impairment. ( 2.1 ) Do not mix with other drugs or administer with dextrose-containing solutions. ( 2.3 )",
    "warningsAndPrecautions": "NDC 0143-9167-01      \n                  Injection: 1 mg/2 mL, in a single-dose vial. One vial per carton.\n                  Store at 25°C (77°F); excursions permitted to 15° to 30° C (59° to 86° F) [see USP Controlled Room Temperature]. Do not freeze or refrigerate. Store the vials in their original cartons.\n                  Eribulin mesylate injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.\n \n  1",
    "adverseReactions": "None."
}